Fujii S - Search Results

1

A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.

Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T. Motohashi S, et al. Among authors: fujii s. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6079-86. doi: 10.1158/1078-0432.CCR-06-0114. Epub 2006 Oct 6. Clin Cancer Res. 2006. PMID: 17028247 Clinical Trial.

2

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.

Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Fujii S, et al. J Exp Med. 2003 Jul 21;198(2):267-79. doi: 10.1084/jem.20030324. J Exp Med. 2003. PMID: 12874260 Free PMC article.

3

Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromes.

Fujii S, Shimizu K, Klimek V, Geller MD, Nimer SD, Dhodapkar MV. Fujii S, et al. Br J Haematol. 2003 Aug;122(4):617-22. doi: 10.1046/j.1365-2141.2003.04465.x. Br J Haematol. 2003. PMID: 12899717 Free article.

4

Valpha14 NKT cell-mediated anti-tumor responses and their clinical application.

Seino K, Fujii S, Harada M, Motohashi S, Nakayama T, Fujisawa T, Taniguchi M. Seino K, et al. Among authors: fujii s. Springer Semin Immunopathol. 2005 Jun;27(1):65-74. doi: 10.1007/s00281-004-0194-y. Epub 2005 Jan 14. Springer Semin Immunopathol. 2005. PMID: 15650847 Review.

5

Application of natural killer T-cells to posttransplantation immunotherapy.

Fujii S. Fujii S. Int J Hematol. 2005 Jan;81(1):1-5. doi: 10.1007/BF02983991. Int J Hematol. 2005. PMID: 15717680 Review.

6

Regulatory balance between the immune response of tumor antigen-specific T-cell receptor gene-transduced CD8 T cells and the suppressive effects of tolerogenic dendritic cells.

Fujii S, Nishimura MI, Lotze MT. Fujii S, et al. Cancer Sci. 2005 Dec;96(12):897-902. doi: 10.1111/j.1349-7006.2005.00124.x. Cancer Sci. 2005. PMID: 16367910 Free PMC article.

7

Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells.

Shimizu K, Hidaka M, Kadowaki N, Makita N, Konishi N, Fujimoto K, Uchiyama T, Kawano F, Taniguchi M, Fujii S. Shimizu K, et al. Among authors: fujii s. J Immunol. 2006 Sep 1;177(5):3484-92. doi: 10.4049/jimmunol.177.5.3484. J Immunol. 2006. PMID: 16920991

8

Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.

Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Shimizu K, et al. Among authors: fujii s. J Immunol. 2007 Mar 1;178(5):2853-61. doi: 10.4049/jimmunol.178.5.2853. J Immunol. 2007. PMID: 17312129

9

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells.

Shimizu K, Kurosawa Y, Taniguchi M, Steinman RM, Fujii S. Shimizu K, et al. Among authors: fujii s. J Exp Med. 2007 Oct 29;204(11):2641-53. doi: 10.1084/jem.20070458. Epub 2007 Oct 8. J Exp Med. 2007. PMID: 17923500 Free PMC article.

10

Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.

Fujii S, Shimizu K, Hemmi H, Steinman RM. Fujii S, et al. Immunol Rev. 2007 Dec;220:183-98. doi: 10.1111/j.1600-065X.2007.00561.x. Immunol Rev. 2007. PMID: 17979847 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,842 results

Search Page

Filters